Orenitram — Cost of Sales
United Therapeutics Orenitram — Cost of Sales increased by 7.2% to $7.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.8%, from $8.30M to $7.40M. Over 4 years (FY 2021 to FY 2025), Orenitram — Cost of Sales shows an upward trend with a 9.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase relative to revenue may signal rising production costs or supply chain inefficiencies, while a decrease suggests improved manufacturing margins.
Detailed definition
Reflects the direct costs associated with the manufacturing, packaging, and distribution of a specific pharmaceutical pr...
Peer comparison
Standard cost of goods sold (COGS) metric found in all manufacturing and pharmaceutical firms.
uthr_segment_orenitram_cost_of_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.80M | $4.50M | $7.30M | $5.20M | $6.40M | $5.60M | $5.20M | $7.60M | $5.70M | $5.70M | $5.20M | $9.20M | $5.90M | $7.60M | $5.70M | $8.30M | $6.70M | $6.80M | $6.90M | $7.40M |
| QoQ Change | — | +18.4% | +62.2% | -28.8% | +23.1% | -12.5% | -7.1% | +46.2% | -25.0% | +0.0% | -8.8% | +76.9% | -35.9% | +28.8% | -25.0% | +45.6% | -19.3% | +1.5% | +1.5% | +7.2% |
| YoY Change | — | — | — | — | +68.4% | +24.4% | -28.8% | +46.2% | -10.9% | +1.8% | +0.0% | +21.1% | +3.5% | +33.3% | +9.6% | -9.8% | +13.6% | -10.5% | +21.1% | -10.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's orenitram — cost of sales?
- United Therapeutics (UTHR) reported orenitram — cost of sales of $7.40M in Q1 2026.
- How has United Therapeutics's orenitram — cost of sales changed year-over-year?
- United Therapeutics's orenitram — cost of sales decreased by 10.8% year-over-year, from $8.30M to $7.40M.
- What is the long-term trend for United Therapeutics's orenitram — cost of sales?
- Over 4 years (2021 to 2025), United Therapeutics's orenitram — cost of sales has grown at a 9.9% compound annual growth rate (CAGR), from $19.70M to $28.70M.
- What does orenitram — cost of sales mean?
- The direct costs incurred to produce and deliver a specific drug to customers.